Teleflex (NYSE:TFX) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Teleflex (NYSE:TFX) had its target price hoisted by research analysts at Wells Fargo & Company from $116.00 to $130.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the medical technology company’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 6.60% from the stock’s current price.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC boosted their target price on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $135.00 price objective on shares of Teleflex in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Truist Financial boosted their price target on shares of Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research report on Thursday, December 18th. Finally, Wall Street Zen lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Teleflex currently has a consensus rating of “Hold” and a consensus price target of $140.71.

Teleflex Trading Up 2.5%

Shares of TFX opened at $121.95 on Friday. The firm has a market cap of $5.39 billion, a P/E ratio of -5.93, a price-to-earnings-growth ratio of 1.59 and a beta of 0.92. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.57 and a quick ratio of 1.53. Teleflex has a 1 year low of $100.18 and a 1 year high of $143.32. The company has a 50 day simple moving average of $111.34 and a two-hundred day simple moving average of $118.71.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). The company had revenue of $569.00 million for the quarter, compared to the consensus estimate of $912.57 million. Teleflex had a positive return on equity of 13.48% and a negative net margin of 30.56%.Teleflex’s revenue was down 28.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.89 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, equities analysts expect that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Trading of Teleflex

Several institutional investors have recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB grew its stake in shares of Teleflex by 57.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after buying an additional 77 shares during the last quarter. Banque Cantonale Vaudoise boosted its holdings in Teleflex by 82.5% during the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after acquiring an additional 113 shares during the period. Hantz Financial Services Inc. grew its position in Teleflex by 40.5% in the 4th quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock valued at $48,000 after acquiring an additional 113 shares during the last quarter. UMB Bank n.a. increased its stake in Teleflex by 57.1% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 113 shares during the period. Finally, Maryland State Retirement & Pension System increased its stake in Teleflex by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock worth $1,056,000 after purchasing an additional 129 shares during the period. Institutional investors own 95.62% of the company’s stock.

Key Teleflex News

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Wells Fargo raised its price target to $130 (from $116) and maintained an “equal weight” rating — a near-term bullish signal that can support buying interest. Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $125 (from $115) with a “sector perform” rating — another analyst lift that helps underpin the rally. Read More.
• Positive Sentiment: Teleflex’s board declared a quarterly cash dividend of $0.34 per share (record date March 6, payable March 31), which can attract income-seeking investors and provide support. Read More.
• Positive Sentiment: The company launched a multi‑year restructuring tied to planned divestitures — investors appear to view this as steps to simplify the portfolio, cut costs and potentially unlock value. Read More.
• Neutral Sentiment: Teleflex published its Q4 presentation and full-year results (material and earnings‑call transcripts are available) — useful for modeling but not a driver by itself. Read More.
• Negative Sentiment: Q4 results missed materially: EPS $1.93 vs. consensus ~$3.73 and revenue $569M vs. ~$912.6M — revenue fell ~28.5% year-over-year and margins contracted, a clear near-term negative for earnings momentum. Read More.
• Negative Sentiment: FY‑2026 guidance was significantly reduced: EPS guidance of $6.25–$6.55 and revenue guidance around $2.3B vs. street expectations materially higher (~$15 EPS and ~$3.7B revenue), which is a major downward re‑rating of near-term expectations. Read More.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.